Trials / Terminated
TerminatedNCT02465112
Metabolic Radiotherapy After Complete Resection of Liver Metastases in Patient With Digestive Neuroendocrine Tumor
A Randomized Phase III of Adjuvant Targeted Radionuclide Therapy With In111-Pentetreotide in Patients With Digestive Neuroendocrine Tumors After Complete Surgical Resection of Liver Metastases.
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
TERAVECT is a phase III randomized study of patients with digestive neuroendocrine tumors after complete surgical resection of liver metastases treated with In111-Pentetreotide-based adjuvant radiotherapy. In this study, targeted radionuclide therapy is used at an earlier stage of the disease.The objective is to target residual tumor cells and/or micrometastases which escaped surgical resection. Given the poor prognosis associated with recurrence, this treatment should prevent relapse.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | In111-Pentetréotide | |
| OTHER | simple monitoring without active therapy |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2018-10-11
- Completion
- 2018-10-11
- First posted
- 2015-06-08
- Last updated
- 2019-02-28
Locations
5 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02465112. Inclusion in this directory is not an endorsement.